Analysis of the diversity of collagen disease treatment response using recombinant inbred mice

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K08735
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Experimental pathology
• Research Institution: Gifu University
• Principal Investigator: Miyazaki Tatsuhiko 岐阜大学, 医学部附属病院, 准教授 (80239384)
• Research Collaborator: SUZUI Natsuko ; KOBAYASHI Kazuhiro ; NODA Touko ; Gröne Hermann-Josef
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: 病理学 / ゲノム / 薬剤反応性 / 炎症・膠原病 / モデル動物 / オステオオンチン

Outline of Final Research Achievements

In order to establish a diversity model of therapeutic response to collagen diseases, recombinant inbred MXH/lpr mice were bred and returned from frozen fertilized eggs to provide mice for experiments. Among Opn and autoantigen-inhibiting proteins, proteins containing a binding epitope with Opn were analyzed and synthesized by a wheat germ cell-free protein synthesis system. In parallel with the in vitro analysis, we developed a drug delivery system (DDS) by lymphatic administration. Cyclophosphamide was administered to patients with glomerulonephritis. Cyclophosphamide was administered to patients with glomerulonephritis. DDS was established, and the effect of treatment was confirmed and adverse events were analyzed.

Free Research Field

実験病理学

Academic Significance and Societal Importance of the Research Achievements

本研究により、多因子疾患である膠原病の治療多様性モデルが確立し、新薬開発等における実験モデルとして有用であることが明らかとなった。
また、膠原病治療のためのリンパ節への薬剤投与という新たなdrug delivery systemの開発を果たし得た。
さらに、Opnの多型部位阻害蛋白の開発は、膠原病治療の新たな治療戦略につながる大きなシーズとなった。今後さらに蛋白製剤の低分子化をすすめ、治療薬として実用化できる方策を進めることが期待される。